Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efinopegdutide (JNJ-64565111) in Non-diabetic Severely Obese Subjects
NCT03486392Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2018
- Primary completion
- Mar 2019
- Modality
- Peptides
- Countries
- 6
01
Overview
A Phase 2 trial of efinopegdutide in obesity, sponsored by Janssen Pharmaceutical. Started Mar 2018; status: completed.
02
Drugs
efinopegdutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03486392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03486392.